Palo Alto Investors LP Revance Therapeutics, Inc. Transaction History

Palo Alto Investors LP

$856 Million
Q1 2024

A detailed history of Palo Alto Investors LP transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Palo Alto Investors LP holds 5,248,004 shares of RVNC stock, worth $13.5 Million. This represents 3.02% of its overall portfolio holdings.

Number of Shares

5,248,004

Previous 5,237,284 0.2%

Holding current value

$13.5 Million

Previous $46 Million 43.91%

% of portfolio

3.02%

Previous 4.21%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.65 - $9.31 $49,848 - $99,803	10,720 Added 0.2%	5,248,004 $25.8 Million
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $50,401 - $97,160	8,675 Added 0.17%	5,237,284 $46 Million
Q2 2023 Aug 14, 2023	SELL	$24.7 - $37.61 $1.03 Million - $1.56 Million	-41,600 Reduced 0.79%	5,228,609 $132 Million
Q1 2023 May 15, 2023	SELL	$18.36 - $35.27 $246,024 - $472,618	-13,400 Reduced 0.25%	5,270,209 $170 Million
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $16.1 Million - $26.9 Million	878,570 Added 19.94%	5,283,609 $97.5 Million

Q2 2022 Aug 15, 2022	SELL	$11.52 - $20.4 $122,688 - $217,259	-10,650 Reduced 0.24%	4,405,039 $60.9 Million
Q1 2022 May 16, 2022	BUY	$12.36 - $20.31 $572,552 - $940,820	46,323 Added 1.06%	4,415,689 $86.1 Million
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $14.5 Million - $32.5 Million	1,167,500 Added 36.46%	4,369,366 $71.3 Million
Q1 2021 May 17, 2021	BUY	$24.03 - $29.97 $12.7 Million - $15.8 Million	528,553 Added 19.77%	3,201,866 $89.5 Million
Q4 2020 Feb 16, 2021	BUY	$23.41 - $28.34 $15.9 Million - $19.2 Million	678,408 Added 34.01%	2,673,313 $75.8 Million
Q3 2020 Nov 16, 2020	BUY	$23.23 - $34.3 $6.75 Million - $9.97 Million	290,533 Added 17.05%	1,994,905 $50.2 Million
Q2 2020 Aug 14, 2020	BUY	$12.6 - $26.55 $13.7 Million - $28.9 Million	1,088,667 Added 176.82%	1,704,372 $41.6 Million
Q1 2020 May 15, 2020	BUY	$12.46 - $27.81 $6.57 Million - $14.7 Million	527,115 Added 595.01%	615,705 $9.11 Million
Q4 2019 Feb 14, 2020	BUY	$11.66 - $20.15 $1.03 Million - $1.79 Million	88,590 New	88,590 $1.44 Million

Others Institutions Holding RVNC

# of Institutions

215

Shares Held

83.4M

Call Options Held

656K

Put Options Held

424K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Palo Alto Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Palo Alto Investors LP with notifications on news.

Account

Palo Alto Investors LP Revance Therapeutics, Inc. Transaction History